Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SOHO 2024 | Potency and efficacy of PIP4K2 inhibitors in ALL: looking forward to first-in-human trials

Eduardo Rego • 6 Sep 2024
SOHO 2024
Acute Lymphoblastic Leukemia Leukemia

Eduardo Rego, MD, University of São Paulo, São Paulo, Brazil, discusses the efficacy of PIP4K2 inhibitors in acute lymphoblastic leukemia (ALL), specifically noting the therapy’s effectiveness against T-cell ALL (T-ALL). Dr Rego looks forward to first-in-human trials with this treatment. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Eduardo Rego

The global expansion of modern AML therapy through the International Consortium on Acute Leukemia 2:44
The global expansion of modern AML therapy through the International Consortium on Acute Leukemia
Eduardo Rego • 6 Sep 2024
The management of Ph+ ALL in resource-constrained settings in South America 1:03
The management of Ph+ ALL in resource-constrained settings in South America
Eduardo Rego • 6 Sep 2024
The main challenges facing practitioners treating APL 0:56
The main challenges facing practitioners treating APL
Eduardo Rego • 18 Apr 2016
Current research on coagulopathy in APL 1:31
Current research on coagulopathy in APL
Eduardo Rego • 19 Apr 2016

Related Videos

The value and mission of the International Workshop on Acute Leukemias 14:36
The value and mission of the International Workshop on Acute Leukemias
Charles Craddock et al. • 21 Oct 2025
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years? 1:30
One big question with Koichi Takahashi: what AML advance could transform frontline care in 3 years?
Koichi Takahashi • 26 Sep 2025
One big question with Naval Daver: what AML advance could transform frontline care in three years? 1:05
One big question with Naval Daver: what AML advance could transform frontline care in three years?
Naval Daver • 26 Sep 2025
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years? 3:13
One big question with Charles Craddock: what AML advance could transform frontline care in 3 years?
Charles Craddock • 26 Sep 2025
The content of VJHemOnc is intended for healthcare professionals